Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

In this retrospective cohort study, tirzepatide dispensations were found to have increased significantly following approval ...

New research to be presented at the European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that around ...

Structure Therapeutics' stock has declined ... and Eli Lilly's (LLY) tirzepatide - approved for the same two indications under the brand names Mounjaro and Zepbound. In 2024, Ozempic, Wegovy ...

New research shows that people who take the weight-loss drug tirzepatide can keep most of the weight off for at least three ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Participants given tirzepatide lowered their HbA1c by a mean 0.77% more than those given a higher dulaglutide dose. More tirzepatide participants hit a weight loss threshold known for disease ...

The trial examined the effect of Eli Lilly’s glucagon-like peptide-1 receptor agonist (GLP-1RA) tirzepatide, which is marketed as Mounjaro, on the clinical trajectory of patients with HFpEF and ...

Both are chronic conditions that progressively worsen over time. Tirzepatide targets two receptors in order to shrink fat cells and reduce the impacts that enlarged fat cells have on heart and ...

Opens in a new tab or window Patients with poorly controlled type 2 diabetes despite being on dulaglutide had better outcomes if they switched to tirzepatide than if they upped their dulaglutide dose.

NEW ORLEANS — For people with type 2 diabetes (T2D) inadequately controlled on submaximal dulaglutide (Trulicity) doses, switching to tirzepatide (Mounjaro) produces significantly greater A1c ...

Note – this is an early press release from the European Congress on Obesity in Malaga, Spain, 11-14 May. Please credit the congress when using this research.* New research to be presented at this year ...